Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Immunogenicity of a Prime-Boost Vaccine Containing the Circumsporozoite Proteins of Plasmodium vivax in Rodents

Full text
Author(s):
Show less -
Teixeira, Lais H. [1, 2] ; Tararam, Cibele A. [1, 2] ; Lasaro, Marcio O. [3] ; Camacho, Ariane G. A. [2, 1] ; Ersching, Jonatan [1, 2] ; Leal, Monica T. [2, 1] ; Herrera, Socrates [4] ; Bruna-Romero, Oscar [5] ; Soares, Irene S. [6] ; Nussenzweig, Ruth S. [7] ; Ertl, Hildegund C. J. [3] ; Nussenzweig, Victor [7] ; Rodrigues, Mauricio M. [1, 2]
Total Authors: 13
Affiliation:
[1] Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Escola Paulista Med, Ctr Terapia Celular & Mol CTCMol, Sao Paulo - Brazil
[3] Wistar Inst Anat & Biol, Philadelphia, PA 19104 - USA
[4] Malaria Vaccine & Drug Dev Ctr, Cali - Colombia
[5] Univ Fed Santa Catarina, Dept Microbiol Imunol & Parasitol, Florianopolis, SC - Brazil
[6] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo - Brazil
[7] NYU, Sch Med, Dept Pathol, Michael Heidelberger Div, New York, NY - USA
Total Affiliations: 7
Document type: Journal article
Source: Infection and Immunity; v. 82, n. 2, p. 793-807, FEB 2014.
Web of Science Citations: 13
Abstract

Plasmodium vivax is the most widespread and the second most prevalent malaria-causing species in the world. Current measures used to control the transmission of this disease would benefit from the development of an efficacious vaccine. In the case of the deadly parasite P. falciparum, the recombinant RTS,S vaccine containing the circumsporozoite antigen (CSP) consistently protects 30 to 50% of human volunteers against infection and is undergoing phase III clinical trials in Africa with similar efficacy. These findings encouraged us to develop a P. vivax vaccine containing the three circulating allelic forms of P. vivax CSP. Toward this goal, we generated three recombinant bacterial proteins representing the CSP alleles, as well as a hybrid polypeptide called PvCSP-All-CSP-epitopes. This hybrid contains the conserved N and C termini of P. vivax CSP and the three variant repeat domains in tandem. We also generated simian and human recombinant replication-defective adenovirus vectors expressing PvCSP-All-CSP-epitopes. Mice immunized with the mixture of recombinant proteins in a formulation containing the adjuvant poly(I.C) developed high and long-lasting serum IgG titers comparable to those elicited by proteins emulsified in complete Freund's adjuvant. Antibody titers were similar in mice immunized with homologous (protein-protein) and heterologous (adenovirus- protein) vaccine regimens. The antibodies recognized the three allelic forms of CSP, reacted to the repeated and nonrepeated regions of CSP, and recognized sporozoites expressing the alleles VK210 and VK247. The vaccine formulations described in this work should be useful for the further development of an anti-P. vivax vaccine. (AU)

FAPESP's process: 12/13032-5 - Generation and analysis of the immunogenicity of recombinant proteins based on the different allelic forms of the circumsporozoite antigen of Plasmodium vivax aiming at the development of a universal vaccine against malaria
Grantee:Irene da Silva Soares
Support type: Research Projects - Thematic Grants